We are live on
!
Find out more
BC
Broadfin Capital Portfolio holdings
AUM
$747M
1-Year Est. Return
100.56%
This Fund
S&P 500
This Quarter
Est. Return
+19.91%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.15B
AUM Growth
+$196M
(+21%)
Cap. Flow
+$54.1M
Cap. Flow
% of AUM
4.71%
Top 10 Holdings %
Top 10 Hldgs %
49.21%
Holding
84
New
12
Increased
28
Reduced
17
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$47.9M |
| 2 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$38.9M |
| 3 |
VOLC
VOLCANO CORPORATION COM STK
VOLC
|
+$18M |
| 4 |
KND
Kindred Healthcare
KND
|
+$12.2M |
| 5 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
+$12.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$33.9M |
| 2 |
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
|
+$19.1M |
| 3 |
IPXL
Impax Laboratories, Inc.
IPXL
|
+$15.6M |
| 4 |
NTUS
Natus Medical Inc
NTUS
|
+$13.7M |
| 5 |
CEMP
Cempra, Inc.
CEMP
|
+$10M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.26% |
| 2 | Consumer Discretionary | 0.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $115M | 10% |
8,917,975
+3,829,092
| +75% | +$47.9M |
|
|
AVDL
2
DELISTED
Avadel Pharmaceuticals
AVDL
| $88.3M | 7.68% |
5,153,190
+147,577
| +3% | +$2.11M |
|
|
PGNX
3
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $67.7M | 5.88% |
8,951,169
| – | – |
|
4
Emergent Biosolutions
EBS
$387M
| $56.3M | 4.89% |
2,066,719
-13,800
| -0.7% | -$329K |
|
|
AEGR
5
DELISTED
Aegerion Pharmaceuticals
AEGR
| $53.4M | 4.64% |
2,548,863
+1,542,301
| +153% | +$38.9M |
|
6
AngioDynamics
ANGO
$549M
| $50.8M | 4.41% |
2,670,703
-304,524
| -10% | -$5.16M |
|
|
VOLC
7
DELISTED
VOLCANO CORPORATION COM STK
VOLC
| $44.6M | 3.88% |
2,494,854
+1,500,000
| +151% | +$18M |
|
8
Travere Therapeutics
TVTX
$5.21B
| $32.5M | 2.83% |
2,658,854
+100,000
| +4% | +$1.03M |
|
|
BDSI
9
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $28.8M | 2.5% |
2,396,399
+363,964
| +18% | +$5.53M |
|
|
PTX
10
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
| $28.6M | 2.49% |
305,000
-45,000
| -13% | -$4.29M |
|
11
Heron Therapeutics
HRTX
$89.1M
| $28.3M | 2.46% |
2,808,173
| – | – |
|
|
ASRT
12
DELISTED
Assertio
ASRT
| $27.6M | 2.4% |
28,562
-10,000
| -26% | -$9.13M |
|
13
Amphastar Pharmaceuticals
AMPH
$866M
| $24.7M | 2.15% |
2,127,854
+150,000
| +8% | +$1.63M |
|
|
AMAG
14
DELISTED
AMAG Pharmaceuticals
AMAG
| $24.4M | 2.13% |
573,530
-937,245
| -62% | -$33.9M |
|
|
PETX
15
DELISTED
Aratana Therapeutics, Inc.
PETX
| $22.4M | 1.95% |
1,259,471
-182,964
| -13% | -$2.28M |
|
|
LJPC
16
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $20.7M | 1.8% |
1,121,370
+14,324
| +1% | +$170K |
|
|
KND
17
DELISTED
Kindred Healthcare
KND
| $20.2M | 1.76% |
1,110,300
+615,000
| +124% | +$12.2M |
|
18
Rigel Pharmaceuticals
RIGL
$736M
| $19.3M | 1.68% |
850,175
+250,373
| +42% | +$5.06M |
|
|
DSCI
19
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $17.3M | 1.5% |
1,856,877
+32,500
| +2% | +$283K |
|
20
AtriCure
ATRC
$1.76B
| $16.5M | 1.43% |
825,902
-100,000
| -11% | -$1.72M |
|
|
ANAC
21
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $16.3M | 1.41% |
504,320
-276,500
| -35% | -$8.3M |
|
|
THOR
22
DELISTED
THORATEC CORPORATION
THOR
| $16.2M | 1.41% |
500,000
| – | – |
|
|
UAM
23
DELISTED
Universal American Corp
UAM
| $16.1M | 1.4% |
1,735,553
-144,806
| -8% | -$1.26M |
|
|
ACGN
24
DELISTED
Aceragen Inc
ACGN
| $15.5M | 1.35% |
25,950
| – | – |
|
|
DVAX
25
DELISTED
Dynavax Technologies
DVAX
| $12.9M | 1.12% |
766,010
| – | – |
|
Similar funds
CBU
CONA
MP
SC
KGACF
BPWA
TRAM
VMI
Broadfin Capital's Q4 2014 Portfolio in Review
As of Q4 2014, Broadfin Capital held 84 positions worth $1.15B, up 21% from $954M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Broadfin Capital deployed $54.1M of net new capital in Q4 2014, opening 12 new positions and adding to 28 existing holdings. Its largest new stake was SALIX PHARMACEUTICALS LTD DEL: 100,000 shares worth $11.5M.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 79% a quarter earlier, followed by Consumer Discretionary.
On the sell side, the largest reduction was AMAG Pharmaceuticals, an estimated $33.9M trimmed.
- Broadfin Capital's largest Q4 2014 buy was SALIX PHARMACEUTICALS LTD DEL: 100,000 shares worth $11.5M.
- Broadfin Capital added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014, an estimated $47.9M increase.
- Broadfin Capital's biggest Q4 2014 reduction was AMAG Pharmaceuticals, cutting an estimated $33.9M.
- Broadfin Capital fully exited Tetraphase Pharmaceuticals, Inc. in Q4 2014, selling an estimated $19.1M.
- Broadfin Capital's ten largest holdings make up 49% of its $1.15B portfolio in Q4 2014.
- Broadfin Capital opened 12 new positions and closed 9 in Q4 2014.
- Broadfin Capital's portfolio value rose 21% quarter-over-quarter to $1.15B.
Based on Broadfin Capital's 13F filing for Q4 2014, filed 17 Feb 2015.